Biotheus Completes $100 Million Funding for Biologic Drugs

Biotheus, a Guangdong biotech, completed a $100 million Series D financing co-led by General Atlantic and IDG Capital. Founded in 2018, Biotheus is developing a broad portfolio of me-better/novel drugs focused on immuno-oncology and metabolic diseases. So far, the company has built a portfolio of 10 innovative monoclonal and multispecific antibodies, with two bispecific antibodies in Phase I trials for cancer and a third IND application under review in China. Biotheus plans to out-license late-stage clinical and commercialization activities to global partners. More details.... Share this with colleagues: // //